MX2015008888A - Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. - Google Patents
Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.Info
- Publication number
- MX2015008888A MX2015008888A MX2015008888A MX2015008888A MX2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- level
- nucleoside transporter
- cancer based
- nucleoside
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000019055 Nucleoside Transport Proteins Human genes 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 108091006527 nucleoside transporters Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 1
- 102000009027 Albumins Human genes 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361848780P | 2013-01-11 | 2013-01-11 | |
| US201361752397P | 2013-01-14 | 2013-01-14 | |
| US13/794,486 US20140199404A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on level of a nucleoside transporter |
| PCT/US2014/011006 WO2014110345A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on level of a nucleoside transporter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015008888A true MX2015008888A (es) | 2015-11-13 |
Family
ID=51165318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008888A MX2015008888A (es) | 2013-01-11 | 2014-01-10 | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140199404A1 (enExample) |
| EP (1) | EP2943191A4 (enExample) |
| JP (1) | JP2016513075A (enExample) |
| CA (1) | CA2897673A1 (enExample) |
| HK (1) | HK1217180A1 (enExample) |
| MX (1) | MX2015008888A (enExample) |
| WO (1) | WO2014110345A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| WO2006089290A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| BR112013027674A2 (pt) | 2011-04-28 | 2016-09-06 | Abraxis Bioscience Llc | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". |
| PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EP3313401B1 (en) | 2015-06-29 | 2021-10-06 | Abraxis BioScience, LLC | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| US11371099B2 (en) | 2015-11-30 | 2022-06-28 | Mayo Foundation For Medical Education And Research | HEATR1 as a marker for chemoresistance |
| EP3522887A4 (en) * | 2016-10-07 | 2020-06-10 | Abraxis BioScience, LLC | METHODS OF TREATING BILARIAN CANCER |
| US11306111B2 (en) | 2017-07-31 | 2022-04-19 | January Therapeutics, Inc. | Organophosphate derivatives |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200204907B (en) * | 2001-06-26 | 2003-03-03 | Univ Nat Taiwan | Collapsin Response Mediator Protein-1. |
| WO2006089290A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2011123393A1 (en) * | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| EP2552453A2 (en) * | 2010-03-30 | 2013-02-06 | Clavis Pharma ASA | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| JP2013527232A (ja) * | 2010-06-02 | 2013-06-27 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんの処置方法 |
| EP2739290A4 (en) * | 2011-08-02 | 2015-04-15 | Clovis Oncology Inc | METHOD FOR SELECTION OF CHEMOTHERAPEUTICS AGAINST ADENOCARCINOMAS |
-
2013
- 2013-03-11 US US13/794,486 patent/US20140199404A1/en not_active Abandoned
-
2014
- 2014-01-10 EP EP14737533.1A patent/EP2943191A4/en not_active Withdrawn
- 2014-01-10 JP JP2015552798A patent/JP2016513075A/ja active Pending
- 2014-01-10 WO PCT/US2014/011006 patent/WO2014110345A1/en not_active Ceased
- 2014-01-10 HK HK16105218.7A patent/HK1217180A1/zh unknown
- 2014-01-10 CA CA2897673A patent/CA2897673A1/en not_active Abandoned
- 2014-01-10 MX MX2015008888A patent/MX2015008888A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2943191A4 (en) | 2016-07-13 |
| WO2014110345A1 (en) | 2014-07-17 |
| CA2897673A1 (en) | 2014-07-17 |
| EP2943191A1 (en) | 2015-11-18 |
| US20140199404A1 (en) | 2014-07-17 |
| JP2016513075A (ja) | 2016-05-12 |
| HK1217180A1 (zh) | 2016-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217180A1 (zh) | 根據一種核苷轉運載體的水平治療癌症的方法 | |
| MX2015008889A (es) | Metodo para tratar cancer con base en el estado de la mutacion k-ras. | |
| MX2021002455A (es) | Metodos para tratar tumores de celulas epitelioides. | |
| MX2018007987A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| HK1220405A1 (zh) | 治疗膀胱癌的方法 | |
| MX2022015755A (es) | Profarmacos de hormona paratiroidea (pth). | |
| IL288342A (en) | Formulations and methods for lyophilic nanoparticulate forms | |
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| PH12016502066A1 (en) | Methods of treating bladder cancer | |
| MX389228B (es) | Composiciones para tratar el cabello. | |
| MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
| MX391017B (es) | Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas. | |
| MX382017B (es) | Metodos para el tratamiento de cancer pancreatico. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| CR20160418A (es) | Nuevos compuestos biciclicos de 7 eslabones | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| HK1220155A1 (zh) | 治疗癌症的方法 | |
| HK1245158A1 (zh) | 阿吡莫德组合物及其使用方法 | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| MX2016009056A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| MX2016003207A (es) | Composiciones que comprenden colina y derivados de esta, usos de las composiciones y procesos para su preparacion. | |
| MX356102B (es) | Compuestos y métodos para tratar leucemia. |